Want to see ACB full AI Analyst Report?
Revenue by Segment
Details income from each business line, providing insight into which segments drive growth and how diversified the company’s revenue streams are.Aurora has clearly pivoted to medical as its core growth engine, driven by international momentum and EU‑GMP capacity builds, while Consumer and Plant Propagation revenues have been deliberately wound down. The April reimbursement cut plus the planned exits will create a near‑term revenue/EBITDA reset in FY27 and more quarter‑to‑quarter volatility, even as higher‑margin medical sales and capacity investments offer a pathway back to stability — investors should trade for execution on international expansion and margin resilience, not near‑term top‑line growth.
Date | Medical Cannabis | Consumer Cannabis | Wholesale Bulk Cannabis | Plant Propagation |
|---|---|---|---|---|
Jun 30, 2026 | C$64.04M | C$2.06M | C$1.46M | C$0.00 |
Mar 31, 2026 | C$77.10M | C$3.65M | C$4.08M | C$0.00 |
Dec 31, 2025 | C$76.25M | C$5.16M | C$1.49M | C$11.30M |
Sep 30, 2025 | C$70.53M | C$6.87M | C$1.41M | C$11.56M |
Jun 30, 2025 | C$64.77M | C$7.88M | C$1.43M | C$23.95M |
Mar 31, 2025 | C$67.78M | C$8.17M | C$826.00K | C$13.77M |
Dec 31, 2024 | C$68.15M | C$9.91M | C$1.24M | C$8.90M |
Sep 30, 2024 | C$61.32M | C$10.42M | C$750.00K | C$8.63M |
Jun 30, 2024 | C$47.20M | C$11.53M | C$1.62M | C$23.08M |
Mar 31, 2024 | C$45.65M | C$10.23M | C$1.11M | C$10.42M |